BJDXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Bluejay Diagnostics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.70−0.05 (-6.46%)

Close on Oct 19, 2026

Market cap: $1.45M
P/E (TTM): –
Dividend yield: –

Bluejay Diagnostics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	–	–	–	0.25	–	–
Cost of Revenue	–	–	–	0.20	–	–
Gross Profit	–	–	–	0.05	–	–
Research & Development	3.05	3.47	5.71	4.15	1.15	0.53
Selling, General & Admin	–	3.70	0.28	0.45	2.08	0.67
Selling & Marketing	–	0.01	0.28	0.45	0.29	0.07
General & Administrative	3.91	3.69	4.31	4.76	1.79	0.60
Operating Expenses	6.95	7.17	10	9.37	3.23	1.20
Operating Income	-6.95	-7.17	-10	-9.32	-3.23	-1.20
Interest Expense	0.00	0.82	–	–	0.01	0.06
Interest & Investment Income	0.10	0.15	0.16	0.09	–	–
Other Non-Operating Income	0.10	-0.55	0.36	0.02	-0.26	0.04
Asset Impairment Charges	0.04	0.00	0.00	0.24	–	–
Gain (Loss) on Sale of Assets	–	0.00	0.00	0.00	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	-3.49	-1.16
Net Income	-6.85	-7.72	-9.95	-9.30	-3.49	-1.16
Net Income to Common	-6.85	-21	-9.95	–	–	–
EPS (Basic)(per share)	-15.25	-456.75	-14,525.92	-14,752.00	-13,120.00	-11,840.00
EPS (Diluted)(per share)	-15.25	-456.75	-14,525.92	-14,752.00	-13,120.00	-11,840.00
Shares Outstanding (Basic, Weighted)(shares)	0.45	0.05	0.00	0.00	0.00	0.00
Shares Outstanding (Diluted, Weighted)(shares)	0.45	0.05	0.00	0.00	0.00	0.00
EBITDA	–	–	–	-9.16	-3.08	-1.04
Net Interest Income	–	–	–	–	-0.37	-0.03

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -117.0%

Financial strength

Current ratio: 4.64
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 453.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.15
Dividend yield: –